- Home
- RIGL vs EQBK Comparison
RIGL vs EQBK Comparison
Compare RIGL & EQBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | EQBK |
|---|---|---|
| Founded | 1996 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.9M | 1.0B |
| IPO Year | 2000 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RIGL | EQBK |
|---|---|---|
| Price | $45.86 | $49.42 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | $45.67 | ★ $51.33 |
| AVG Volume (30 Days) | ★ 206.3K | 74.1K |
| Earning Date | 05-05-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 1.59% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | 1.32 | ★ 2.06 |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | N/A | $74.58 |
| Revenue Next Year | $12.75 | $5.11 |
| P/E Ratio | $34.00 | ★ $24.40 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $38.60 |
| 52 Week High | $52.24 | $52.27 |
Technical Indicators
Market Signals| Indicator | RIGL | EQBK |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 51.77 |
| Support Level | $40.05 | $44.45 |
| Resistance Level | $49.50 | $51.93 |
| Average True Range (ATR) | 1.45 | 1.00 |
| MACD | -0.61 | 0.03 |
| Stochastic Oscillator | 17.89 | 48.55 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.